186 related articles for article (PubMed ID: 3009615)
1. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
2. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2).
Siaw MF; Nemerow GR; Cooper NR
J Immunol; 1986 Jun; 136(11):4146-51. PubMed ID: 3009616
[TBL] [Abstract][Full Text] [Related]
4. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
5. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
6. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
8. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
Tedder TF; Goldmacher VS; Lambert JM; Schlossman SF
J Immunol; 1986 Aug; 137(4):1387-91. PubMed ID: 3016095
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes.
Barel M; Fiandino A; Delcayre AX; Lyamani F; Frade R
J Immunol; 1988 Sep; 141(5):1590-5. PubMed ID: 2842398
[TBL] [Abstract][Full Text] [Related]
10. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
11. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
12. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
13. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
[TBL] [Abstract][Full Text] [Related]
14. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
15. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
Nemerow GR; Wolfert R; McNaughton ME; Cooper NR
J Virol; 1985 Aug; 55(2):347-51. PubMed ID: 2410629
[TBL] [Abstract][Full Text] [Related]
17. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.
Nemerow GR; Siaw MF; Cooper NR
J Virol; 1986 May; 58(2):709-12. PubMed ID: 2422399
[TBL] [Abstract][Full Text] [Related]
18. Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells.
Cantaloube JF; Piechaczyk M; Calender A; Lenoir G; Minty A; Carrière D; Fischer E; Poncelet P
Eur J Immunol; 1990 Feb; 20(2):409-16. PubMed ID: 1690137
[TBL] [Abstract][Full Text] [Related]
19. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
